Q-omics provides the consensus-scored HOXC5 profile across patient tissues and cancer cell-line models. HOXC5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, HOXC5 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, HOXC5 RNA expression shows 15,358 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, BLCA, and TGCT as cancer lineages where HOXC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXC5 survival associations across molecular data types. HOXC5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXC5 RNA expression–survival associations across cancer types. High HOXC5 expression shows unfavorable associations in COAD, HNSC, LGG and LUAD, but favorable associations in MESO and BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for HOXC5 RNA expression.
This table summarizes HOXC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for HOXC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXC5 shows lower tumor expression in UCEC, STAD and THCA and higher tumor expression in BLCA, HNSC and LUSC. The BLCA box plot shows higher HOXC5 RNA expression in tumor versus normal tissue (log2 FC = +0.146, t-test p = .003).
This table shows molecular features associated with HOXC5 in patient tissues and cancer cell lines. In patient samples, HOXC5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
